Holen Sie sich die Stockscreener-App
9.55
4.37%
0.40
Handel nachbörslich:
9.69
0.14
+1.47%
Replimune Group Inc Aktie (REPL) Neueste Nachrichten
GAMMA Investing LLC Boosts Stock Position in Replimune Group, Inc. (NASDAQ:REPL) - Defense World
Replimune Group, Inc. (NASDAQ:REPL) Shares Sold by Bank of America Corp DE - Defense World
California State Teachers Retirement System Boosts Holdings in Replimune Group, Inc. (NASDAQ:REPL) - Defense World
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Sells 15,402 Shares of Replimune Group, Inc. (NASDAQ:REPL) - Defense World
Squarepoint Ops LLC Cuts Stock Position in Replimune Group, Inc. (NASDAQ:REPL) - Defense World
Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | REPL Stock News - GuruFocus
Replimune Group, Inc. Grants Inducement Equity Awards to New Employees Under 2025 Plan - Nasdaq
Replimune Group, Inc. (REPL) Stock Analysis: A Biotech Gem with 124% Potential Upside - DirectorsTalk Interviews
JPMorgan reiterates overweight rating on Replimune stock after ASCO By Investing.com - Investing.com Canada
Replimune Group (NASDAQ:REPL) Price Target Raised to $22.00 at Piper Sandler - Defense World
Piper Sandler raises Replimune stock price target after updates By Investing.com - Investing.com South Africa
Piper Sandler raises Replimune stock price target after updates - Investing.com Australia
Does Replimune Group Inc (NASDAQ: REPL) Still Need To Convince Analysts? - Stocksregister
Replimune Group (REPL) Price Target Raised by Piper Sandler Anal - GuruFocus
Replimune Group (REPL) Price Target Raised by Piper Sandler Analyst | REPL Stock News - GuruFocus
Replimune (REPL) Price Target Raised by Piper Sandler Amid Positive Developments | REPL Stock News - GuruFocus
BNP Paribas Financial Markets Trims Stake in Replimune Group, Inc. (NASDAQ:REPL) - Defense World
Replimune (REPL) Highlights Promising RP1 Data at ASCO 2025 | REPL Stock News - GuruFocus
Replimune Presents New Analyses from the IGNYTE Study of RP1 plu - GuruFocus
Replimune Presents New Analyses from the IGNYTE Study of RP1 plus Nivolumab in Anti-PD1 Failed Melanoma at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting | REPL Stock News - GuruFocus
Replimune Reports Promising Clinical Data for RP1 Plus Nivolumab at ASCO 2025, Highlighting Robust Responses and Safety Profile - Nasdaq
Replimune Presents New Analyses From The IGNYTE Study Of RP1 Plus Nivolumab In Anti-PD1 Failed Melanoma At The 2025 American Society Of Clinical Oncology (ASCO) Annual Meeting - marketscreener.com
Replimune Presents New Analyses from the IGNYTE Study of RP1 plus Nivolumab in Anti-PD1 Failed ... - Enidnews.com
Replimune's RP1 Achieves 33% Response Rate in Anti-PD1 Failed Melanoma Trial | REPL Stock News - Stock Titan
ProShare Advisors LLC Grows Stock Position in Replimune Group, Inc. (NASDAQ:REPL) - Defense World
Replimune Group (NASDAQ:REPL) Trading Down 5.9% – Time to Sell? - Defense World
Replimune Group, Inc. (NASDAQ:REPL) Receives Consensus Rating of “Buy” from Analysts - Defense World
Replimune to Present at the 2025 Jefferies Global Healthcare Conference - The Manila Times
Replimune Group, Inc. (NASDAQ:REPL) Shares Acquired by Nuveen Asset Management LLC - Defense World
Why Okta Stock Plunged on Wednesday - The Globe and Mail
HC Wainwright Estimates Replimune Group Q3 Earnings - Defense World
Leerink Partnrs Estimates Replimune Group Q1 Earnings - Defense World
Replimune’s SWOT analysis: biotech firm’s stock poised for growth amid FDA review - Investing.com India
Replimune director sells $260,168 in common stock By Investing.com - Investing.com South Africa
Replimune Group, Inc. (NASDAQ:REPL) Q4 2025 Earnings Call Transcript - Insider Monkey
Replimune (REPL) Plans Major Stock Sale with 25.1M Shares Offeri - GuruFocus
Replimune Group Inc Files For Offer & Resale Of 25.1 Million Shares Of Common Stock Offered By Selling StockholdersSEC Filing - marketscreener.com
Replimune Group Inc Files For Mixed Shelf Of Up To $250 MillionSEC Filing - marketscreener.com
Replimune (REPL) Announces $250 Million Securities Shelf Filing | REPL Stock News - GuruFocus
Replimune Group, Inc. (REPL) Stock Analysis: An Insight into a Biotech Gem with 141% Upside Potential - DirectorsTalk Interviews
Replimune Group Inc (REPL) Q4 2025 Earnings Call Highlights: Strategic Advances Amid Financial ... - Yahoo Finance
Stock Traders Buy High Volume of Call Options on Replimune Group (NASDAQ:REPL) - Defense World
Replimune Group Inc (REPL) Q4 2025 Earnings Call Highlights: Strategic Advances Amid Financial Challenges - GuruFocus
Replimune director sells $260,168 in common stock - Investing.com Australia
Replimune Group Advances Oncolytic Immunotherapy Pipeline - TipRanks
Replimune’s chief commercial officer sells $30,179 in stock By Investing.com - Investing.com South Africa
Replimune Group, Inc. SEC 10-K Report - TradingView
REPLIMUNE GROUP Earnings Results: $REPL Reports Quarterly Earnings - Nasdaq
1.45%
0.86%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):